Physician profile
Kimberly Ryckeley
NPI 1396264255
$2,171.17
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $785 · 2022: $659 · 2023: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $598.90 | 2021-2023 | Valtoco |
| Ucb, INC. | $395.58 | 2021-2023 | Briviact, Fintepla |
| Ironshore Pharmaceuticals INC. | $286.94 | 2021-2023 | Jornay Pm |
| Corium, LLC | $211.74 | 2021-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $133.96 | 2021-2023 | Qelbree |
| Aquestive Therapeutics, INC. | $114.80 | 2021-2022 | |
| Pfizer INC. | $114.59 | 2021-2023 | |
| Baxter Healthcare | $87.40 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Adlon Therapeutics L.P. | $49.87 | 2021 | |
| Advanced Respiratory, INC | $40.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.83 | 2021-2022 | |
| Owp Pharmaceuticals, INC. | $24.11 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.24 | 2022 | |
| Uswm, LLC | $20.00 | 2021 | |
| Novo Nordisk INC | $17.69 | 2023 | Wegovy, Saxenda |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $14.24 | 2023 | Lyvispah |
| Zogenix INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ryckeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.